



COVID-19 IMMUNITY
TASK FORCE

Spotlight on CITF-FUNDED RESEARCH



CITF Announcements

New CITF Databank page with data dashboard

We have revamped our CITF Databank page to make it more user-friendly. We've also created a new **CITF Data Dashboard** which displays descriptive data about studies that have contributed individual-level data to the CITF Databank. The interactive dashboard allows you to filter information by study, study population/sub-population, participant gender, age, and collection dates or individual studies.

[Discover](#)



CITF-Funded Research Results

Seroprevalence due to infection among Canadian blood donors reached the 80% mark in June

The latest CITF-funded report from Canadian Blood Services suggests that the 80% mark in estimated infection-acquired seroprevalence among Canadian adults was reached by June 30, 2023. The percentage of younger donors (ages 17-24) who had infection-acquired seroprevalence surpassed 90%. Self-declared Indigenous and racialized donors continued to have higher seroprevalence due to infection than did self-declared white donors.

[Read more](#)

Adults of all ages mount robust T-cell responses to COVID-19 vaccination, which are further boosted by breakthrough infection

A CITF-funded study, published in preprint and not yet peer-reviewed, found that adults, including older adults (65-93 years), mount robust T-cell responses to two- and three-dose COVID-19 mRNA vaccination. A following breakthrough infection boosts them even further.

[Read more](#)

Intimate partner violence was highly prevalent among gay, bisexual, and other men who have sex with men

An ongoing cohort study that received funding from the CITF did a sub-study which found that many gay, bisexual, and other men who have sex with men (GBM) had experienced or had perpetrated intimate partner violence (IPV) in their lifetime. The research, published in preprint and not yet peer-reviewed, found that approximately 1 in 3 participants had reported experiencing physical and/or sexual IPV and 17% had reported being the one inflicting IPV. The prevalence of IPV among GBM was stable over the past six months in Montreal, Toronto, and Vancouver.

[Read more](#)

CITF-funded findings on pan-Canadian serosurveillance

CITF-funded studies monitoring both infection-acquired and vaccine-induced seroprevalence over time have been – and will continue to be – key to understanding the spread of the virus. They are also crucial to identify populations potentially more susceptible to infection, severe disease, and death. Here, we summarize results from the five presentations given during the “Pan-Canadian serosurveillance” breakout session at the CITF Scientific Meeting in Vancouver, March 8-10, 2023. The study teams presented seroprevalence data from different age groups and regions, distinct pandemic phases, and in relation to the number of vaccine doses received, offering a broad view of seroprevalence across the country.

[Read more](#)



Share!

Know policymakers or researchers who may be interested in our latest research results? Please share this email and encourage them to subscribe!

[Sign Up](#)

Have a publication we should review or know about? Please share with us at research@covid19immunitytaskforce.ca

Missed an issue of Spotlight on CITF-Funded Research? [View back issues.](#)

The views expressed herein do not necessarily represent the views of the
Public Health Agency of Canada.